EGFR and non-small cell lung carcinoma: Thus, Osimertinib is licensed for first-line treatment of stage IV NSCLC with EGFR activating mutations and for patients who developed central nervous system metastasis and for whom progressed on first/second-generation EGFR TKIs due to T790M resistance mutation.